Canada's BioSyent Q1 revenue rises helped by Oral Science acquisition

Biosyent

14/05/2026 23:11

Overview

Canada specialty healthcare firm's Q1 revenue rose 27% yr/yr, driven by Oral Science acquisition

Q1 adjusted EPS was C$0.22, up C$0.02 from year ago; no analyst estimates provided

Company repurchased 100,000 shares under NCIB and raised quarterly dividend by 10%

Outlook

Company cites uncertainty in business environment due to Middle East conflict and trade protectionism

BioSyent says it is positioned to pursue growth with a diversified portfolio after Oral Science acquisition

Result Drivers

ORAL SCIENCE ACQUISITION - Acquisition of Oral Science added C$3.0 mln in sales and contributed to profit in March, per CEO René Goehrum

PHARMACEUTICAL SALES GROWTH - Canadian pharmaceutical sales rose 9%, led by FeraMAX and Tibella brands, per CEO René Goehrum

INTERNATIONAL SALES MIXED - Continued shipments of FeraMAX to Middle East despite geopolitical turmoil; Tibelia sales declined due to prior-year backlog deliveries, per CEO René Goehrum

Company press release: ID:nGNXc9VrTK

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
C$0.20


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)